Aurobindo Pharma Limited — PPTs, 04-08-2025: Investor Presentation

Here's a summary of Aurobindo Pharma Limited's Q1FY26 earnings:

**1. Financial Highlights:**

Aurobindo Pharma's Q1FY26 revenue grew 4% YoY to ₹7,868 Cr. EBITDA decreased 1% to ₹1,603 Cr (20.4% margin), and Net Profit fell 10.2% to ₹824 Cr. Strong European (+18% YoY) and ARV (+55.2% YoY) growth offset a decline in US revenue (lower lenalidomide) and a 16.1% drop in API sales. Net cash position stands at ~₹120 Cr.

**2. Strategic Initiatives & Growth Drivers:**

Net capex of ~₹63 Cr supports expansion. R&D spend of ₹367 Cr focuses on biosimilars, with Dazublys (trastuzumab biosimilar) securing European authorization and Dyrupeg gaining UK approval. European commercial supplies are expected by Q3/Q4 FY26, with first US submission planned for FY26.

**3. Business Developments:**

US operations saw 4 ANDAs filed, 14 products approved, and 15 launched. ARV business boosted. Its biosimilar arm, CuraTeQ, has three products authorized by European authorities; its manufacturing facility received WHO GMP certification.

**4. Market Position & Competitive Advantage:**

Aurobindo maintains a strong global portfolio. Its expanding biosimilar pipeline and regulatory successes indicate a strategic pivot towards high-value biologics, positioning it for long-term differentiation and growth.

**5. Investor Implications:**

Top-line growth is evident, but profitability decline warrants monitoring. The strategic focus on biosimilars, with pipeline progress and upcoming market entries, presents significant positive growth potential.